CITIUS ONCOLOGY, INC. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that CITIUS ONCOLOGY, INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | ($24.76M) | Dec 23, 2025 |
| FY2025 | Sep 30, 2024 | ($21.15M) | Dec 23, 2025 |
| FY2023 | Dec 31, 2023 | $2.42M | Apr 16, 2024 |
| FY2024 | Sep 30, 2023 | ($12.70M) | Dec 27, 2024 |
| FY2023 | Dec 31, 2022 | $380.8K | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | ($10.1K) | Apr 17, 2023 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | ($23.52M) | Dec 23, 2025 |
| FY2025 | Sep 30, 2024 | ($20.57M) | Dec 23, 2025 |
| FY2023 | Dec 31, 2023 | ($1.01M) | Apr 16, 2024 |
| FY2023 | Dec 31, 2022 | ($138.1K) | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | ($10.1K) | Apr 17, 2023 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $6.42M | Dec 23, 2025 |
| FY2025 | Sep 30, 2024 | $4.93M | Dec 23, 2025 |
| FY2024 | Sep 30, 2023 | $4.24M | Dec 27, 2024 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | ($5.49M) | Dec 23, 2025 |
| FY2025 | Sep 30, 2024 | $126.4K | Dec 23, 2025 |
| FY2023 | Dec 31, 2023 | ($601.3K) | Apr 16, 2024 |
| FY2023 | Dec 31, 2022 | ($48.0K) | Apr 16, 2024 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $100.94M | Dec 23, 2025 |
| FY2025 | Sep 30, 2024 | $84.37M | Dec 23, 2025 |
| FY2023 | Dec 31, 2023 | $72.62M | Apr 16, 2024 |
| FY2024 | Sep 30, 2023 | $47.73M | Dec 27, 2024 |
| FY2023 | Dec 31, 2022 | $68.19M | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | $126.4K | Apr 17, 2023 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $56.08M | Dec 23, 2025 |
| FY2025 | Sep 30, 2024 | $38.23M | Dec 23, 2025 |
| FY2024 | Sep 30, 2023 | $22.20M | Dec 27, 2024 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $44.87M | Dec 23, 2025 |
| FY2025 | Sep 30, 2024 | $46.14M | Dec 23, 2025 |
| FY2023 | Dec 31, 2023 | ($1.99M) | Apr 16, 2024 |
| FY2025 | Sep 30, 2023 | $25.54M | Dec 23, 2025 |
| FY2023 | Dec 31, 2022 | $345.5K | Apr 16, 2024 |
| FY2024 | Sep 30, 2022 | $36.27M | Dec 27, 2024 |
| FY2023 | Dec 31, 2021 | ($10.1K) | Apr 16, 2024 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | ($64.04M) | Dec 23, 2025 |
| FY2025 | Sep 30, 2024 | ($39.28M) | Dec 23, 2025 |
| FY2023 | Dec 31, 2023 | ($1.99M) | Apr 16, 2024 |
| FY2024 | Sep 30, 2023 | ($18.13M) | Dec 27, 2024 |
| FY2023 | Dec 31, 2022 | $345.3K | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | ($10.1K) | Apr 17, 2023 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | 0 | Dec 23, 2025 |
| FY2025 | Sep 30, 2024 | 0 | Dec 23, 2025 |
| FY2023 | Dec 31, 2023 | 0 | Apr 16, 2024 |
| FY2024 | Sep 30, 2023 | 0 | Dec 27, 2024 |
| FY2023 | Dec 31, 2022 | 0 | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Apr 17, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | 0 | Dec 23, 2025 |
| FY2025 | Sep 30, 2024 | 0 | Dec 23, 2025 |
| FY2023 | Dec 31, 2023 | 0 | Apr 16, 2024 |
| FY2024 | Sep 30, 2023 | 0 | Dec 27, 2024 |
| FY2023 | Dec 31, 2022 | 0 | Apr 16, 2024 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | 83.51M | Dec 23, 2025 |
| FY2025 | Sep 30, 2024 | 71.55M | Dec 23, 2025 |
| FY2023 | Dec 31, 2023 | 2.34M | Apr 16, 2024 |
| FY2024 | Sep 30, 2023 | 67.50M | Dec 27, 2024 |
| FY2023 | Dec 31, 2022 | 2.42M | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | 2.42M | Apr 17, 2023 |